Инфезол 40

Quick links

Choose a section

Quick links to important sections

Advertisements

Инфезол 40

Selected form

Advertisements
Advertisements

Treatment option: Parenteral Nutrition, Delivery

Advertisements

Overview of Инфезол 40

Quick Facts

Property Description
Active Ingredients Balanced mixture of L-Amino Acids (Essential & Non-Essential)
Form Solution for infusion
Pharmacological Class Agents for Parenteral Nutrition / Amino Acid Solution
General Purpose Metabolic support; maintaining protein balance
Origin Manufactured (Synthetic)

What is Инфезол 40?

Инфезол 40: What is it and what is its pharmaceutical form?

Инфезол 40 is a specific, prescription-only solution for infusion, recognized in the therapeutic class of agents for parenteral nutrition. It is a sterile, clear aqueous solution intended for direct delivery into a vein. As a complex pharmaceutical product, it is a manufactured/synthetic formulation, ensuring the precise balance and purity required for safe systemic administration when patients cannot receive adequate nutrition via the digestive tract.

What is the composition and pharmacological class of Инфезол 40?

Инфезол 40 is chemically defined as an amino acid solution, placing it in the pharmacological class of agents for parenteral nutrition. Its composition is characterized by a carefully balanced mixture of both essential and non-essential L-amino acids. The inclusion of these vital protein building blocks is crucial for meeting patient protein needs. This precise formulation is designed to replace amino acid losses and support the body's natural protein synthesis processes.

What is the therapeutic purpose of Инфезол 40?

The primary therapeutic purpose of Инфезол 40 is to provide reliable metabolic and protein support, essential in situations of high physiological stress or malnutrition. It serves as a necessary component of a parenteral feeding regimen, used to prevent or treat a negative nitrogen balance. These intravenous amino acid solutions are indicated for providing nutritional support, highlighting their critical role in protecting the body against protein deficit during recovery from severe illness or surgery.

Advertisements

What side effects are possible with Инфезол 40?

Possible Side Effects and Safety Information

The safety profile for Инфезол 40 is structured according to regulatory classifications, detailing officially documented adverse reactions and crucial constraints. The potential for undesirable effects is generally classified as Very Rare.

Adverse Reactions Scope

Adverse effects are categorized by the system-organ class affected, based on regulatory labeling:

  • General Disorders and Administration Site Conditions: Reactions may include chills, increased sweating, or pyrexia (fever). Local irritation at the infusion site, such as vein wall irritation or thrombophlebitis, is also documented.
  • Gastrointestinal and Systemic Effects: Nausea and vomiting are listed, along with systemic effects like head pain and tachycardia (increased heart rate).
  • Immune System Disorders: The label includes the risk of severe reactions, including anaphylactic reactions.

Key Safety Constraints and Special Populations

The use of Инфезол 40 is governed by several contraindications documented in official safety information. It must not be administered in patients with severe, decompensated hepatic or renal impairment, established amino acid metabolism disorders, metabolic acidosis, hyperkalemia, or unstable circulatory conditions.

Dose- or Exposure-Related Patterns:

  • Certain systemic effects, such as nausea and chills, may be associated with an infusion rate that is too rapid.
  • There is a documented risk of aluminum toxicity when parenteral nutrition solutions are used for prolonged periods, especially in patients with impaired kidney function.

Population-Specific Notes: The solution is not recommended for children under 3 years of age. Caution is required for patients with asthma due to the presence of sodium metabisulfite, which may trigger allergic-type reactions.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Intravenous Amino Acid Solutions outlines specific overdose manifestations primarily associated with an excessively high dose or infusion rate.

Category Documented Manifestation or Outcome
Intolerance Reactions Nausea, Vomiting, Shivering, Headache
Fluid & Metabolic Hyperhydration, Electrolyte Imbalance, Metabolic Acidosis
Severe Outcomes Pulmonary Oedema, Hyperammonaemia, Pulmonary Vascular Precipitates

Emergency Actions Mandated by Regulators

The regulatory guidance strictly requires immediate action in the event of suspected overdose or adverse reaction. If signs of intolerance reactions (e.g., nausea or shivering) are observed, the infusion must be temporarily interrupted and may be resumed later at a lower rate.

However, the onset of severe symptoms, including any signs of pulmonary distress or a generalized hypersensitivity reaction, requires the infusion to be stopped immediately. In such cases, or if serious outcomes like Pulmonary Oedema or severe Hyperammonaemia are suspected, urgent medical evaluation must be initiated. The management of overdose is symptomatic and supportive, as no specific antidote is known. Close monitoring of fluid status is required, especially for newborns and patients with renal or hepatic insufficiency.

Advertisements

Therapeutic Uses of Инфезол 40

Инфезол 40 is a specific solution administered by intravenous infusion and is employed as part of parenteral nutrition. The primary use of this medical therapy is to provide essential nutritional support for individuals who are temporarily unable to take nourishment orally or enterally, such as following surgical procedures, severe trauma, or in other clinical states that prevent normal dietary intake.

The core benefit of Инфезол 40 is its role in preventing or treating protein deficiency (negative nitrogen balance) in the body. It delivers a comprehensive profile of amino acids, which serve as the fundamental building blocks for protein synthesis and tissue repair. This therapeutic action is critical for promoting healing and maintaining body structure and function, particularly in states of increased metabolic demand, such as after burns or significant blood loss.

Furthermore, the solution supplies necessary electrolytes and a source of energy (xylitol) to support overall fluid and metabolic balance. The proper administration of amino acids and electrolytes through parenteral nutrition is a key element in intensive medical care to facilitate patient recovery.


Quick Facts: Инфезол 40

  • Therapeutic Domain: Parenteral Nutrition Support.
  • Main Function: Prevents and treats protein loss and protein deficiency.
  • Conditions Managed: States of increased protein requirement or impaired intake (e.g., post-surgery, trauma, burns).
  • Primary Benefit: Provides essential amino acids for protein synthesis and tissue repair.

Regulatory References

  1. NIH MedlinePlus guidance on parenteral nutrition
Advertisements

Eligibility and Restrictions for Use

Eligibility for Инфезол 40: Official Regulatory Profile

Инфезол 40 (Amino Acid Solution for Infusion) is primarily approved for use in adults and adolescents requiring essential nutritional support, as documented in official prescribing information. Eligibility is strictly determined by the patient's underlying health status and organ function, particularly their capacity to safely process the amino acid load and the fluid volume.


Contraindicated Populations (Must Not Use)

Use of Инфезол 40 is absolutely contraindicated in patients presenting with the following conditions:

  • Severe organ failure: Severe renal insufficiency, anuria, severe hepatic insufficiency, or hepatic coma.
  • Severe metabolic disturbances: Inborn errors of amino acid metabolism or severe, non-compensated metabolic acidosis.
  • Circulatory overload: Pathological hyperhydration, non-compensated cardiac insufficiency, or pulmonary oedema.

Conditional Use and Age Restrictions

Population Group Regulatory Status
Chronic Renal/Hepatic Impairment Conditional use only; requires close monitoring and dose adjustment.
Infants and Toddlers Use is generally not established or not recommended; may require specialized formulations.
Pregnancy/Lactation Use only if clearly necessary following a rigorous benefit-to-risk assessment.

Older adults are permitted to use the medicine but require caution due to the higher prevalence of underlying organ dysfunction.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation confirms that Инфезол 40, an amino acid solution used for parenteral nutrition, is not associated with the majority of typical drug–drug interactions (DDIs). The official interaction profile is structured by the general absence of documented pharmacokinetic interactions, such as those involving Cytochrome P450 (CYP) enzymes or drug transport proteins (e.g., P-gp).

Documented Interacting Substances

The only specific interaction officially documented with a medicinal product relates to tetracycline. Co-administration with tetracycline may reduce the potential intended effect of the infused amino acids.

Category Officially Documented Statement
Specific Interacting Medicine Tetracycline
Interaction Effect May reduce the potential effect of the amino acids

Interaction-Related Restrictions

Official labeling imposes a critical restriction based on solution stability and compatibility: the addition of other medicinal products into the infusion container must generally be avoided. This restriction is due to the significant risk of physical or chemical incompatibility and precipitation, which is separate from pharmacokinetic or pharmacodynamic interactions.

No interactions with food, alcohol, herbal products, or supplements are officially documented for this intravenous solution.

Advertisements

Mechanism of Action

Covalent Enzyme Inhibition in Gastric Cells

This mechanism initiates when the active compound, selectively accumulated in the acidic secretory canaliculi of the gastric parietal cells, undergoes a proton-catalyzed activation. The activated drug intermediate then forms a covalent, irreversible disulfide bond with specific cysteine residues on the luminal surface of the H^+/ K^+-ATPase enzyme system.

Modification of Acid Secretion Pathway

The irreversible binding to the H^+/ K^+-ATPase, commonly known as the proton pump, prevents its final conformational change and translocation activity. This action directly inhibits the exchange of potassium ( K^+) for hydrogen ions ( H^+) across the cellular membrane, thereby suppressing both basal and stimulus-driven gastric acid secretion. The duration of the antisecretory effect is governed by the subsequent turnover rate of the affected enzyme molecules, leading to sustained physiological modulation of the gastric environment.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Инфезол 40

Инфезол 40 is a solution for infusion and must be administered strictly via intravenous infusion (IV), typically in a hospital setting where specialized medical supervision is available. It is not for direct oral or topical use.

Dosing and Frequency

Usage Parameter Official Regulatory Instruction
Route of Administration Intravenous infusion. Central venous access is recommended for prolonged or highly concentrated regimens.
Standard Adult Dose Calculated as 1.0 g to 2.0 g of amino acids per kg of body weight per day (g AA/kg/day), depending on the patient's metabolic needs.
Maximum Rate The infusion rate should not exceed 0.1 g of amino acids per kg of body weight per hour to ensure safe assimilation.
Frequency Pattern Administered as a continuous infusion, often over 14 to 24 hours as part of the overall regimen.
Duration of Use Continues until the patient can transition to adequate oral or enteral nutrition.

Preparation and Special Conditions

Preparation: The solution should only be used if it is clear and the container is undamaged. Инфезол 40 is only one component of nutritional support; it must be administered as part of a complete parenteral nutrition (PN) regimen which includes other essential non-protein energy sources, such as dextrose and fat emulsions. The final admixture must be prepared using careful aseptic technique.

Population Adjustments: Dosage must be individually adjusted and reduced for patients with renal impairment or hepatic insufficiency to prevent metabolite accumulation.

Special Constraint: Инфезол 40 must not be mixed with other medicinal products unless compatibility is specifically verified by a healthcare professional, as additives may cause incompatibilities. The solution or admixture must be inspected immediately prior to and periodically during administration.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Инфезол 40

This overview describes the types of research and general findings for the class of intravenous amino acid solutions, such as Инфезол 40. The information here outlines what scientists have studied and what remains unclear, based on regulatory evidence and peer-reviewed literature.

Evidence for Metabolic Support in Critically Ill Patients

Research examining amino acid solutions for patients under severe physiological strain, such as those in the Intensive Care Unit (ICU), often involves Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies were evaluated in adult populations with high protein demand. Research in this setting examined primary clinical outcomes such as patient survival and resource utilization, measured by the length of time patients spent in the ICU and hospital.

Findings described patterns related to metabolic balance, and research describes how the solutions introduce components that serve as building blocks for protein synthesis and tissue repair. However, the data show patterns related to survival and length of stay that were observed in some studies to be mixed. Research describes how the results may be complex due to patients in the ICU having widely varying underlying health conditions and needs.

Evidence for General Parenteral Nutrition and Protein Balance

Research into the general use of amino acid solutions was studied for its ability to provide necessary protein when a patient cannot eat normally. These studies include metabolic research using tracers to accurately measure Net Protein Balance and Nitrogen Balance—the body's process of using and losing protein. Research describes how the solution was studied to influence protein status in various medical and surgical inpatients who require intravenous feeding.

Comparative evidence is lacking for the specific formulation of a standard solution like Инфезол 40 versus other widely available standard amino acid solutions; most research focuses on the class as a whole or on formulations containing added specialized components. Because the follow-up durations were limited to the acute hospital phase, the long-term impact on patient well-being after discharge is not fully established.

What is Still Uncertain About Amino Acid Solutions

While a significant volume of research was studied for the metabolic effects of amino acid solutions, several areas are still emerging or remain unclear. Limited information for long-term outcomes is a key limitation, as most trials prioritize short-term acute care results. Research also highlights that the results apply only to the specific populations studied, and research does not determine whether an individual will respond similarly. Evidence quality varies across studies due to differences in design and patient populations. This variability means that conclusions regarding the optimal use of these solutions in all clinical scenarios are often still the subject of ongoing research.

Key Studies & References Parenteral Nutrition - NIH MedlinePlus guidance

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Инфезол 40 (FAQ)

Q: What are the most commonly reported side effects of Инфезол 40?

A: Regulatory documents state that adverse reactions for this medicine are generally categorized as Very Rare. Documented effects include systemic reactions such as chills, increased sweating, pyrexia (fever), nausea, vomiting, and headache. Local reactions at the infusion site, like vein wall irritation, are also described in the official product information.

Q: Are the side effects of Инфезол 40 usually serious?

A: The majority of documented reactions are temporary systemic or local effects. However, official safety information also includes the potential risk for severe reactions, such as anaphylactic reactions. This balance of potential risks is considered during medical administration.

Q: Does Инфезол 40 affect blood pressure?

A: The official safety profile lists tachycardia (increased heart rate) as a documented effect, though a direct change in blood pressure is not specifically listed. The solution is officially contraindicated in patients with already unstable circulatory conditions. The solution is administered only under medical supervision, which allows for careful monitoring of circulatory conditions.

Q: Is it safe to use Инфезол 40 if I have kidney problems?

A: According to official regulatory information, use is strictly contraindicated (must not be used) in cases of severe kidney failure or anuria. For patients with chronic kidney impairment that is not severe, use is conditional, requiring close monitoring and careful dose consideration by a healthcare professional.

Q: Is it safe to use Инфезол 40 if I have liver problems?

A: Official information states that the medicine is contraindicated in cases of severe liver failure or hepatic coma. In less severe cases of chronic liver impairment, use is conditional, requiring careful dose consideration and close monitoring by a healthcare professional.

Q: Can Инфезол 40 be used at the same time as antibiotics?

A: The only specific medicinal product interaction documented is with tetracycline, which may reduce the intended nutritional effect of the amino acids. Separate from this, official guidelines strongly restrict mixing other medicines directly into the infusion container due to the high risk of chemical incompatibility or precipitation.

Q: Does Инфезол 40 interact with common over-the-counter pain relievers?

A: Regulatory documentation states that no interactions with over-the-counter pain relievers are specifically documented. The interaction profile highlights an issue only with the prescription drug tetracycline and emphasizes caution against mixing any other substances into the infusion container.

Q: Is there a maximum time a person can safely use Инфезол 40?

A: The duration of use is defined by the patient's continuing nutritional need and lasts until they can transition to adequate oral or enteral feeding. However, official safety information notes a documented risk of aluminum toxicity when parenteral nutrition solutions are used for prolonged periods, especially in patients with impaired kidney function.

Q: What are the criteria for discontinuing the use of Инфезол 40?

A: The primary criterion for stopping the solution is when the patient transitions to adequate nutrition via the digestive tract. Additionally, the drug must be discontinued if the patient develops specific severe conditions listed as contraindications in the safety information, such as severe metabolic disturbances or severe organ failure.

Q: How does Инфезол 40 compare to other common solutions for the same issue?

A: Research indicates that comparative evidence is generally lacking for this specific standard amino acid formulation versus other widely available standard amino acid solutions. Studies often focus on the performance of the general drug class rather than on subtle differences between standard formulations.

Q: Can I stop using Инфезол 40 suddenly if I feel better?

A: The solution is administered as a continuous infusion over a sustained period (often 14 to 24 hours) as part of a complete nutritional regimen. Its use continues for as long as necessary to meet the patient's metabolic needs until they can transition to adequate oral or enteral nutrition.

Q: What should I do if I miss a scheduled time for Инфезол 40?

A: This medication is administered as a continuous infusion in a controlled hospital environment as part of a highly supervised medical regimen. Any required adjustments to the infusion rate or schedule are managed directly by the healthcare team overseeing the patient's complete nutritional support plan.

Q: Is there a lot of research supporting the use of Инфезол 40?

A: Research supporting the use of this class of solutions is extensive, including Randomized Controlled Trials (RCTs) and metabolic research. These studies examine the solution's role in providing necessary protein and metabolic support for patients under severe stress, such as those in intensive care.

Q: Why do doctors call this medicine by a different name sometimes?

A: As a type of pharmaceutical product, this medicine belongs to the general class of Agents for Parenteral Nutrition. Chemically, it is classified as an Amino Acid Solution containing a balanced mixture of L-Amino Acids, which are the generic chemical components of the product.

Q: Does Инфезол 40 cause sleepiness or affect driving ability?

A: Official safety information does not list sleepiness or give a warning about effects on driving ability. Since the solution is administered via intravenous infusion in a clinical setting, official documentation does not typically include warnings about affecting a patient’s ability to drive.

Q: Do people typically need to take other supplements with Инфезол 40?

A: Yes, regulatory documentation states that Инфезол 40 is only one component of nutritional support. It must be administered as part of a complete parenteral nutrition (PN) regimen which includes other essential non-protein energy sources, such as dextrose and fat emulsions, to meet the body's total caloric needs.

Q: Is Инфезол 40 considered a first-line treatment?

A: The therapeutic purpose of the solution is to provide essential metabolic support and prevent protein deficit when a patient cannot receive adequate nutrition via the digestive tract (the natural route). It serves as a necessary intervention when oral or enteral feeding is insufficient or impossible.

Q: Why is it important to complete the full course of Инфезол 40?

A: The solution is used to prevent or treat a negative nitrogen balance, providing necessary building blocks for protein synthesis and repair. Completing the necessary duration ensures the patient maintains adequate protein status until they can safely transition back to oral or enteral nutrition.

Q: Does Инфезол 40 have any effects on blood sugar levels?

A: The amino acid solution itself is administered as part of a complete nutritional regimen that includes other non-protein energy sources, such as dextrose, which is a form of glucose. These additional components are relevant to blood sugar management and require careful monitoring by medical staff.

Q: What is the risk of aluminum toxicity with Инфезол 40?

A: Official safety constraints note a documented risk of aluminum toxicity when parenteral nutrition solutions are used for prolonged periods. This risk is particularly noted for patients who have impaired kidney function, which makes it harder for the body to clear the aluminum.

Q: Does Инфезол 40 contain any allergens like gluten or lactose?

A: A key component mentioned in the safety constraints is sodium metabisulfite. This inactive ingredient may potentially trigger allergic-type reactions, such as bronchial spasms, in sensitive patients, including those with asthma.

Q: What kind of studies have been done on the long-term use of Инфезол 40?

A: Studies examining the effects of these solutions often limit follow-up durations to the acute hospital phase of illness or recovery. Because of this, official documentation states that the long-term impact on patient well-being after discharge is not fully established.

Q: Why is this medication only available via a prescription?

A: Инфезол 40 is classified as a prescription-only solution due to its complex nature and route of administration. It is intended for direct delivery via intravenous infusion as part of specialized nutritional support, which requires a clinical setting and expert medical supervision.

Q: Can Інфезол 40 be used with herbal remedies?

A: The official interaction profile states that no specific interactions with herbal products or dietary supplements are officially documented for this intravenous solution. Nevertheless, the solution is administered in a controlled clinical environment.

Q: Are there any dietary restrictions associated with Инфезол 40?

A: No specific interactions with food are officially documented. The solution itself is administered when the patient cannot eat normally, providing necessary protein support to meet metabolic needs.

Q: How does a doctor decide the right strength of Инфезол 40 to use?

A: The standard adult dose is calculated by the healthcare provider based on the patient's individual body weight and their specific metabolic needs. Official guidelines provide a range of amino acids per kilogram of body weight per day to guide this calculation.

Q: What should a patient know about the inactive ingredients in Инфезол 40?

A: A key inactive ingredient (excipient) noted in the safety documentation is sodium metabisulfite. This component carries a warning because it may trigger allergic-type reactions, particularly in sensitive patients such as those with asthma.

Advertisements

How should Инфезол 40 be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal of Инфезол 40 (an amino acid solution for infusion) must strictly follow the conditions detailed in the official regulatory documentation to maintain product integrity and safety.

Storage Category Requirement according to Regulatory Labeling
Maximum Temperature Store at a temperature no higher than 25°C (77°F).
Light Protection Must be stored in a place protected from light.
Prohibited Environment Do not freeze!
Stability after Opening Must be used immediately after opening the vial or bottle.
Child Safety Keep the medicinal product out of the sight and reach of children.

Disposal

Any unused portion of the product or related waste materials must be disposed of in accordance with local pharmaceutical waste requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Инфезол 40 found in:

A-Z Index: